Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (58)

2024

  1. Cross-sectional analysis of a cohort of people over 65 years of age living with HIV

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 6, pp. 317-320

2023

  1. Effects of frailty, geriatric syndromes, and comorbidity on mortality and quality of life in older adults with HIV

    BMC Geriatrics, Vol. 23, Núm. 1

2022

  1. Different profiles among older adults with HIV according to their chronological age and the year of HIV diagnosis: The FUNCFRAIL cohort study (GeSIDA 9817)

    PloS one, Vol. 17, Núm. 3, pp. e0266191

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Patient-Reported Outcomes (PROs) in HIV Infection: Points to Consider and Challenges

    Infectious Diseases and Therapy, Vol. 11, Núm. 5, pp. 2017-2033

  4. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir

    Drug design, development and therapy, Vol. 16, pp. 827-841

2021

  1. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

    AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293

  2. Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018

    PLoS ONE, Vol. 16, Núm. 4 April

  3. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

    BMC Health Services Research, Vol. 21, Núm. 1

  4. New horizons in the pharmaceutical care of HIV patients on long-term antiretroviral treatment

    Farmacia Hospitalaria

  5. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

  6. “I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

    Culture, Health and Sexuality, Vol. 23, Núm. 8, pp. 1066-1078

2020

  1. Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

    AIDS and Behavior, Vol. 24, Núm. 12, pp. 3473-3481

  2. LipoDDx: A mobile application for identification of rare lipodystrophy syndromes

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

  3. Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

    AIDS and Behavior, Vol. 24, Núm. 12, pp. 3533-3544

  4. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

  5. Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy

    Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 149-154

2019

  1. HIV pre-exposure prophylaxis (PrEP) in Spain: political and administrative situation

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 656-660

  2. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505

2018

  1. Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017

    PLoS ONE, Vol. 13, Núm. 10